The group's principal activities are research, development and commercialization of transcription factors for regulation of gene expression. the group's gene recognition-tm- technology platform is a proprietary technology enabling the engineering of a class of transcription factors known as zinc finger dna-binding proteins (zfps). universal gene recognition enables the technology, which is widely applicable to pharmaceutical discovery, development of human therapeutics, clinical diagnostics, and plant agricultural and industrial biotechnology. the group intends to commercialize its technology on its applications. the group operates only in domestic market. the group acquired gendaq limited in 2001. collaboration agreements accounted for 97% of 2001 revenues and federal government research grants, 3%.